Tag Archives: Roche Group

TCP-Ventana, CBRE, WEB

Ventana leases 60KSf build-to-suit in Marana

An affiliate of Cottonwood Properties announced they will be constructing and leasing a 60,000 square foot distribution facility for Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group. The new facility is located in Tangerine Commerce Park located on Tangerine Farms Road just west of the Tangerine Road freeway interchange. This is the first development within the 100-acre business park that provides a range of retail and employment uses and will be a key location for future employment and retail growth in the Marana area. Financial terms of the transaction were not disclosed.

Bill Di Vito and Jesse Blum with CBRE’s Tucson office represented Cottonwood in the transaction. Ventana Medical Systems, Inc. was represented by Dev Gupta with DTZ.

“The Tangerine Corridor is an ideal location for this type of development,” said CBRE’s Di Vito. “Freeway access and the availability of larger commercial parcels will attract other logistics and employment users to the area, establishing it as the next major commercial hub in greater Tucson.”

The distribution facility is being designed by Gromatzky Dupree and Associates and construction with Barker Morrissey Contracting is scheduled to start in 4Q 2014 with completion projected for 4Q 2015.

Ventana Medical Systems, Inc., headquartered in Oro Valley, Ariz., is a member of the Roche Group and is a world leader and innovator of tissue-based cancer diagnostic solutions for patients worldwide. At its existing facility, located in the master-planned business community of Innovation Park, Ventana delivers medical diagnostic systems and biopsy-based cancer tests that are shaping the future of healthcare. This new facility will function as a multi-use distribution facility with some assembly to support its facility in Oro Valley.

Tangerine Commerce Park is located just off Interstate-10 on Tangerine Road and is the only mixed-use and industrial development along the quickly developing Tangerine Corridor with direct access to Oro Valley and the bio-tech industries. The park can accommodate uses from smaller 2- to 3-acre requirements up to 100-acre requirements.

medical.research

TGen, Ventana announce research collaboration

The Translational Genomics Research Institute (TGen) and Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer.

The two Arizona-based institutions will leverage each other’s expertise in discovery and diagnostic product development, bringing innovative cancer diagnostic tests to patients.

The first project under the umbrella research agreement will focus on diagnostic, prognostic and drug biomarkers for pancreatic cancer, the fourth leading cause of death from cancer in the United States. This year, an estimated 45,000 people will be diagnosed and more than 38,000 patients will die from the disease. Worldwide, more than 213,000 are diagnosed with pancreatic cancer each year, and the numbers are growing. Fewer than 1 in 4 pancreatic cancer patients survive more than a year, and fewer than 6 percent survive more than five years – the worst survival rate of any cancer.

This dismal picture of pancreatic cancer is mainly due to the lack of tools for early detection and the ineffectiveness of current therapeutics. This is why new diagnostic markers and more efficacious therapies are desperately needed.

“TGen is on the cutting edge of translational research, where investigators discover the genetic components of disease,” says Jeffrey Trent, Ph.D., President and Research Director of TGen. “Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today.”

“When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment,” says Ventana President and CEO Mara G. Aspinall. “As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to improve the lives of all patients afflicted with cancer. We are thrilled to be able to pursue this with a partner right in our Arizona backyard.”